The thesis
SilentDip rests on a clean behavioural idea: a sharp price drop with no negative headline behind it is more likely noise than news, and noise reverts. When the same drop carries genuine bad news, it tends to keep drifting lower. So the strategy only buys names that are both technically oversold and free of salient negative sentiment, then exits as price mean-reverts to its 20-day SMA or RSI normalises.
The work is grounded in recent academic research — Clinch, He, Landsman & Li's November 2025 SSRN working paper From Drift to Reversal, which extends Chan's canonical 2003 study on how prices react to news versus no-news. It is encouraging to see a live strategy anchored to a specific, citable mechanism rather than a curve-fit.
Backtest and validation
Over 1,279 trading days the backtest returned 52.62% (final equity $15,262 from $10,000), an 8.69% CAGR, with a Sharpe of 1.03, a 10.38% max drawdown, and a strong 70.55% win rate across 294 trades. That is a respectable, low-drawdown profile.
Validation is the real highlight. All four walk-forward folds were positive, the most recent two markedly so (fold 3: +26.26%, Sharpe 1.84; fold 4: +16.75%, Sharpe 1.91, with drawdown falling to just 2.39%). Out-of-sample return of 16.75% and OOS Sharpe of 1.91 are reassuring, and the probabilistic Sharpe ratio of 0.991 suggests the edge is unlikely to be pure luck.
Risks worth flagging
Balance demands caution on three fronts. First, the deflated Sharpe ratio is only 0.563 — after accounting for 42 trials, the strategy's statistical edge is positive but far from overwhelming, a reminder that selection bias was in play during development. Second, the early folds were weak: fold 1 returned 4.96% and fold 2 just 1.91%, so the headline numbers lean heavily on the strong 2024–2026 period. Third, turnover of 4,192% is very high for a 24-name large-cap book; the backtest's fee assumptions look light ($294 total, zero FX), and real-world slippage on this churn could erode the edge meaningfully.
Live so far
SilentDip deployed on 11 October with $10,000, having been approved at a low risk score of 0.32 (the reviewer flagged only a non-zero-price guard gap and a sizing nuance). It sat entirely in cash for three days — fittingly patient for a strategy that waits for quiet dips — before its first execution on 14 October: 29 shares of BAC at $51. Total equity sits at $9,994.71, a hair below par, consistent with early entry friction.
Verdict
SilentDip is a well-motivated, well-validated mean-reversion strategy with a genuine academic spine and a low-drawdown track record. The modest deflated Sharpe and heavy turnover are the caveats to watch. With only one position on and days of live history, it has earned a place on the board — but not yet a verdict.